The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2529
Abstract: Neutropenia is a dose‐related treatment‐limiting and costly adverse event of pemetrexed. We postulate that individualized dosing reduces the incidence of neutropenia. The aims of this study were (i) to investigate the costs of pemetrexed‐related neutropenia… read more here.
Keywords: neutropenia incidence; pharmacoeconomic benefits; dosing pemetrexed; incidence ... See more keywords
Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.01.018
Abstract: OBJECTIVES Pemetrexed is indicated for non-small cell lung cancer and mesothelioma. Dosing is based on body surface are (BSA), while renal function is the only determinant for exposure and thus toxicity. BSA-based dosing introduces large… read more here.
Keywords: dosing pemetrexed; guided dosing; impairment; pharmacokinetically guided ... See more keywords